Vanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review HETLIOZ™ NDA

 Vanda Pharmaceuticals Stock Trading Halted; FDA Advisory Committee to Review
                                 HETLIOZ™ NDA

PR Newswire

WASHINGTON, Nov. 14, 2013

WASHINGTON, Nov. 14, 2013 /PRNewswire/ --Vanda Pharmaceuticals Inc. (VANDA)
(NASDAQ: VNDA), a biopharmaceutical company focused on the development and
commercialization of products for the treatment of central nervous system
disorders, today announced that NASDAQ halted trading of Vanda common stock
this morning. 

The Peripheral and Central Nervous System Drugs Advisory Committee to the U.S.
Food and Drug Administration (FDA) meets today to review Vanda's New Drug
Application (NDA) for tasimelteon, proposed trade name HETLIOZ™, for the
treatment of Non-24-Hour Disorder in the totally blind. The Advisory
Committee meeting is scheduled for 8:00 am ET.

Vanda's HETLIOZ™ NDA is currently under Priority Review by the FDA with an
action target date under the Prescription Drug User Fee Act (PDUFA-V) of
January 31, 2014. 

Investor Contact:
Chad Rubin
Vice President
The Trout Group
(646) 378-2947
crubin@troutgroup.com

Media Contact:
Laney Landsman
Assistant Vice President
Makovsky
(212) 508-9643
llandsman@makovsky.com

SOURCE Vanda Pharmaceuticals Inc.

Website: http://www.vandapharma.com
 
Press spacebar to pause and continue. Press esc to stop.